GlassScriptPhysician profile
Brian Edward Rogers
NPI 1760558001
$6,811.08
in general payments reported to CMS, 2019-2025
38 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $732 · 2021: $994 · 2022: $917 · 2023: $1,118 · 2024: $1,116 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,467.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,185.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $867.93 | 2021-2025 | Vraylar |
| Abbott Laboratories | $693.49 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $618.26 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $480.01 | 2019-2025 | |
| Amgen INC. | $448.43 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $391.51 | 2019-2025 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $297.82 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.71 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $202.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $201.08 | 2019-2023 | Myrbetriq, Veozah |
| Eisai INC. | $182.86 | 2020-2022 | |
| Exact Sciences Corporation | $110.54 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $92.37 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $84.14 | 2019-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.